Recursion Pharmaceuticals is trading $3.62 (+5.09%) with no verified direct catalyst identified.
- No confirmed company-specific announcement or analyst action was found for September 4, 2026; recent coverage instead centers on August’s Q2 results and pipeline updates.
- Broader sentiment is modestly mixed, so the reason remains uncertain rather than clearly market-driven.
- Recent insider selling was reported on September 2.